|Pronunciation||dak" oh mi' ti nib|
|Elimination half-life||70 hrs|
|Excretion||79% faeces, 3% urine|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||469.95 g·mol−1|
|3D model (JSmol)|
Dacomitinib has advanced to several Phase III clinical trials.[when?] The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing[when?].
Dacomitinib was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019, for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.
- "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services.
- Chustecka Z (27 January 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape.
- Taylor P (28 January 2014). "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com.
- "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. 27 January 2014.
- Smith M (6 June 2017). "Dacomitinib Sets PFS Record in Phase III NSCLC Trial". MedPage Today.
- Shirley M (December 2018). "Dacomitinib: First Global Approval". Drugs. 78 (18): 1947–1953. doi:10.1007/s40265-018-1028-x. PMID 30506139. S2CID 54034570.
- "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Retrieved 13 December 2019.
- "Dacomitinib". Drug Information Portal. U.S. National Library of Medicine.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|